AHA Coding Clinic® for HCPCS - 2021 Quarter 1; In this Issue
Monoclonal antibody treatments for novel coronavirus (COVID-19)
When a patient is administered the antihistamine diphenhydramine during the same encounter for the infusion of bamlanivimab, does the hierarchy related to drug administration for facility reporting apply? Would the diphenhydramine be considered an initial or subsequent administration? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article explains how outpatient monoclonal antibody treatments for COVID-19 were addressed during the public health emergency and how related HCPCS Level II reporting evolved. It is aimed at coding professionals, billers, and reimbursement staff who need to understand the general scope of the treatments, the emergency authorization context, and the kinds of coding questions that arose around administration and reporting. The article also situates these treatments alongside other COVID-19 code categories and discusses general outpatient and facility reporting considerations.
Why This Topic Matters
COVID-19 treatment coding changed rapidly during the public health emergency, and this article helps readers understand the reporting framework for monoclonal antibody therapies in outpatient settings. It is relevant for accurate charge capture, claims processing, and staying aligned with evolving HCPCS Level II guidance.
Article Sections
-
COVID-19 coding background and monoclonal antibody overview
Introduces the broader COVID-19 coding environment and explains the article’s focus on outpatient monoclonal antibody treatments. It also places these therapies within the larger set of pandemic-related code developments.
-
Emergency use authorizations and treatment context
Summarizes the emergency authorization backdrop for several monoclonal antibody therapies and the general clinical context in which they were used. This section also notes the outpatient setting and associated care environment considerations.
-
HCPCS Level II codes for monoclonal antibody treatments
Presents the HCPCS Level II reporting framework associated with the therapies discussed in the article and identifies the timing of code availability. The section is organized around the outpatient treatment categories covered in the source.
-
Reporting questions and administration considerations
Addresses common reporting questions that arose in connection with these therapies, including how related medications and infusion situations were viewed in the outpatient setting. The section also touches on modifier use and facility reporting topics at a general level.
What You Will Learn
- How outpatient monoclonal antibody treatment coding fit into the COVID-19 public health emergency
- Which broad HCPCS Level II categories were used for these therapies
- What the article says about emergency authorization and outpatient administration context
- How the article frames related reporting questions for infusion encounters
- What general coding considerations were raised for facility reporting and modifiers
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Outpatient facility coding staff
- Reimbursement professionals
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com